anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Network connectivity, as mapped by the whole brain connectome, plays a crucial role in regulating auditory function. Auditory deprivation such as unilateral hearing loss might alter structural network connectivity; however, these potential alterations are poorly understood. Thirty-seven acoustic neuroma patients with unilateral hearing loss (19 left-sided and 18 right-sided) and 19 healthy controls underwent diffusion-weighted and T1-weighted imaging to assess edge strength, node strength, and global efficiency of the structural connectome. Edge strength was estimated by pair-wise normalized streamline density from tractography and connectomics. Node strength and global efficiency were calculated through graph theory analysis of the connectome. Pure-tone audiometry and word recognition scores were used to correlate the degree and duration of unilateral hearing loss with node strength and global efficiency. We demonstrate significantly stronger edge strength and node strength through the visual network, weaker edge strength and node strength in the somatomotor network, and stronger global efficiency in the unilateral hearing loss patients. No discernible correlations were observed between the degree and duration of unilateral hearing loss and the measures of node strength or global efficiency. These findings contribute to our understanding of the role of structural connectivity in hearing by facilitating visual network upregulation and somatomotor network downregulation after unilateral hearing loss.
Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
The invention relates to a traditional Chinese medicine composition for treating cancer and a cocktail therapy thereof. The composition is a medicament prepared by the following bulk drugs according to parts by weight: 5 parts of corydalis tuber, 6 parts of rhodiola root, 9 parts of leech, 9 parts of centipede, 9 parts of sanguisorba, 9 parts of trametes robiniphila murr, 3 parts of giant knotweed, 3 parts of Herba Lycopi, 7 parts of radix bupleuri, 4 parts of selfheal and 2 parts of Clematis chinensis. The invention also relates to a preparation method for adding the composition in cocktail to be brewed and then administrated, commonly referred to as 'cokctail therapy'. The composition has functions of inhibiting tumor cells, reducing obstruction and eliminating stagnation, stimulating the menstrual flow and removing stasis, promoting blood circulation, strengthening immune function, getting rid of the stale and bringing forth the fresh, building body, keeping health and the like. What is more, the 'cocktail therapy' is unique and marked in effect. The traditional Chinese medicine composition has good healing effect especially on lung cancer, liver cancer and esophagus cancer.
PURPOSE:To provide a second solution for cold-wave lotion containing a specific oxidizing agent, effective in preventing the lowering of the elasticity of hair and applicable without damaging the hair. CONSTITUTION:The objective solution contains at least one kind of compound selected from riboflavin, its derivative (e.g. flavin adenine dinucleotide, flavin mononucleotide and riboflavin phosphate) and glutathione as an oxidizing agent. A liquid compounded with thioglycolic acid can be used as it is as the 1st solution for cold-wave lotion. Hair is treated with the 1st solution and then the 2nd solution containing the specific oxidizing agent. Elasticity of hair can be recovered to about 90% or more by immersing hair in the 2nd solution for several hours and the effect is especially remarkable in the case of repeated cold-wave treatment.
Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Sham devices are programmed to display a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes, but no current will be emitted from the device. Participants will not be able to adjust the settings on the devices.
Participants in home expansion group will perform the saline injection for their right tissue expander under clinic staff supervision on their 2nd and 3rd expansion. Beginning their 4th expansion, participants will perform saline injection at home prior to their regularly scheduled clinic visit.
Wheat blast caused by Pyricularia oryzae pathotype Triticum (MoT) has been transmitted from South America to Bangladesh and Zambia and is now spreading in these countries. To prepare against its further spread to Asian countries, we introduced Rmg8, a gene for resistance to wheat blast, into a Japanese elite cultivar, Chikugoizumi (ChI), through recurrent backcrosses and established ChI near-isogenic lines, #2-1-10 with the Rmg8/Rmg8 genotype and #4-2-10 with the rmg8/rmg8 genotype. A molecular analysis suggested that at least 96.6% of the #2-1-10 genome was derived from the recurrent parent ChI. The #2-1-10 line was resistant to MoT not only in primary leaves at the seedling stage but also in spikes and flag leaves at the heading stage. The strength of the resistance in spikes of this Rmg8 carrier was comparable to that of a carrier of the 2NS segment, which has been the only genetic resource released to farmers' fields for wheat blast resistance. On the other hand, the 2NS resistance was not expressed on leaves at the seedling stage nor flag leaves at the heading stage. Considering that leaf blast has been increasingly reported and regarded as an important inoculum source for spike blast, Rmg8 expressed at both the seedling and heading stages, or more strictly in both leaves and spikes, is suggested to be useful to prevent the spread of MoT in Asia and Africa.
For each study participant we recorded their age, sex, state they lived in, tumor type, tumor location, recent sun exposure (during the two weeks prior to the surgery), whether or not a follicle was present on the slide, and if so the follicular extension (mm) from the granular layer, presence of atypia, nesting, pagetoid spread. Two slides were obtained; one stained with Mart-1; the other with H\&E. For both, melanocyte counts per high power field (400 X HPF magnification) were obtained in three locations of the slide. The mean of the 3 counts was used for analysis, though the individual counts were considered in some data summaries (see below). Classification of photo-aging according to the Glogau scale was noted by the surgeon as type1: "no wrinkles"; type II "wrinkles in motion"; type III "wrinkles at rest" and type IV "only wrinkles." Confluence was categorized by the number of adjacent melanocytes as none, mild (2 side-by-side), moderate (3-6), or severe (7 or more).
This study is an observational study to describe the conditions of occurrence of arrhythmias, particularly atrial fibrillation, in patients supported by VA ECMO, as well as their short-term and long-term prognosis. Patients will be recruited from the intensive care units and CRFs will be completed by the investigators at each of the participating centers. Data will be collected directly from the medical records, except for vital status at 1 year, which may be collected by telephone from the patient by the investigator at the center in the absence of data in the medical record.

Atrial fibrillation episodes will be recorded on a 12-lead electrocardiogram and securely transmitted to the coordinating center. In addition, investigators will send weekly data to the principal investigator for incidence calculation. Patients or their relatives will be informed about the study by an information sheet presented and explained by the investigator or another person authorized to conduct the research. The investigator will record the patient's consent in the patient's medical record.
In the first intervention period the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
Patients with resectable solid tumors of various origins such as but not limited to breast-, prostate-, bladder cancer, Head\&Neck SCC, oesophageal SCC and sarcoma will be treated with the regimen assessed as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If \>2 major pathological responses are observed accrual will continue to a total of 18 patients.
Continuous administration of magnesium sulfate beyond 5 to 7 days in pregnant women can lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia. In addition, cases of neonatal fracture have been reported. 

Neonates of women receiving Magnesium Sulfate in 5% Dextrose Injection (especially with prolonged maternal use) are at risk for magnesium toxicity including hyporeflexia, hypotonia, and respiratory depression. There is one reported case of neonatal death as the result of magnesium toxicity after transplacental exposure. 

The shortest duration of magnesium sulfate treatment that can lead to fetal harm is not known. Administration of Magnesium Sulfate in 5% Dextrose Injection beyond 5 to 7 days is not recommended.
This study examines a community pharmacy-based intervention to reduce opioid medication misuse. Despite a recent national decline in opioid prescribing, 10.3 million Americans in 2018 reported misusing a prescribed opioid, and within this population, \>36% of those who misused obtained the opioid medication by filling a prescription. The point of medication dispensing, namely, the community pharmacy, is an untapped resource to address prescription opioid misuse-especially when considering the \>60,000 pharmacies employing \>170,000 pharmacists in the US. This study aims to conduct a fully-powered RCT of the BI-MTM intervention in community pharmacy settings that will accomplish 3 Specific Aims. The first Aim will demonstrate the pharmacist-led BI-MTM intervention is superior to standard medication counseling (SMC) for mitigating opioid medication misuse. This will be accomplished by conducting a powered single-blinded randomized trial to test the efficacy of BI-MTM (n=175) vs. SMC (n=175). Participants will be screened/recruited for eligibility at point of dispensing in 14 community pharmacies in Utah, a high opioid prescribing and opioid-adverse event state. Participants will be assessed at baseline, 2, and 6 months for opioid medication misuse. Participant-level state prescription drug monitoring data will also be linked with patient outcomes to assess objective changes in medication misuse behaviors (e.g., early refills and doctor/pharmacy shopping). The second Aim will identify the pathway by which BI-MTM results in improvements for depression, pain, and subsequently opioid misuse. To accomplish this, a path analysis will assess relationships of BI-MTM: (1) on depression, pain, and misuse, (2) depression on misuse, and (3) pain on misuse. The final Aim will explore latent transitions of baseline to post-intervention misuse classes by intervention group. This will be accomplished by using mixture modeling, specifically multi-group latent transition analysis. The observed misuse indicators will be used to estimate latent class transitions across time, grouping by treatment condition and adjusting for baseline covariates. Completing SA1- 3 advance the understanding of BI-MTM efficacy and set the stage for a national multisite trial.
BACKGROUND: Randomized controlled trials (RCTs) suggested breast conserving therapy (BCT) and mastectomy have similar survival for early-stage breast cancer, whereas observational studies reported survival advantage for BCT. We aimed to address biases in observational studies to compare the effect of BCT and mastectomy on survival.
METHODS: We emulated a target trial using institutional cancer registry. We included adult women diagnosed with early invasive first primary breast tumors ≤ 5 cm between July 2011 and December 2017. We used cloning, censoring, and weighting to estimate risk differences (RDs) and risk ratios (RRs) for all-cause mortality and recurrence or all-cause mortality between BCT and mastectomy (reference).
RESULTS: Our study population comprised 534 observations with breast cancer. Median age was 56 years and 65 % were racial/ethnic minorities. The 8-year RD was 1.5 % (95 % confidence limits [CL]: -7.0 %, 9.8 %) and RR was 1.1 (95 % CL: 0.57, 2.2) for all-cause mortality. Results for recurrence or mortality were similar.
CONCLUSIONS: Our results suggest that target trial emulation to mitigate selection and immortal-time biases in observational studies may generate estimates that are more compatible with RCTs when comparing the effects of BCT and mastectomy on survival. Studies with longer follow-up and more events are needed to confirm our findings.
PROBLEM TO BE SOLVED: To obtain a sound hair agent for preventing damaging of hair and curing damaged hair, having effects to recover beauty and health inherent to the hair and safe to human body by bringing the agent to contain an ammonium salt and a specific compound. SOLUTION: This sound hair agent contains an ammonium salt, its ion and one or more species of ingredients selected from compounds expressed by the formula [R1 to R3 are each H, OH, a (substituted) lower alkoxy or the like; R4 and R5 are each H, OH, an (OH or amino substituted) lower alkyl or aryl, carboxy or the like; R6 and R7 are each H, an (OH substituted) lower alkyl, a lower alkylcarbonyl, aryl, or aralky], (e.g. L-arginine, etc.), their ions and salts. Preferably, the compound of the formula is L-arginine and the agent further contains another compound expressed by the formula (e.g. ethanolamine, etc.), and a natural preparation (e.g. a rice preparation, etc.), in addition to L-arginine and the ammonium salt.
Methods and compositions for producing single-stranded cDNA (ss-cDNA) in eukaryotic cells, specifically, a DNA cassette that produces ss-cDNA in vivo. The cassette contains the Moloney murine leukemia virus reverse transcriptase/RNAse H coding gene, a bacterial restriction endonuclease gene, and a sequence of interest which produces an RNA template from which the reverse transcriptase synthesizes ss-cDNA of a specified sequence. The ss-cDNA is then modified to remove all flanking vector sequences by taking advantage of the 'stem-loop' structure of the ss-cDNA, which forms as a result of the inclusion of an inverted tandem repeat that allows the ss-cDNA to fold back on itself, forming a double stranded DNA stem, in the sequence of interest. The double-stranded stem contains one or more functional genetic elements such as a restriction endonuclease recognition site and the loop, which remains as ss-DNA, is comprised of any desired nucleotide sequence. This design allows the double-stranded stem of the stem-loop intermediate to be cleaved by the desired corresponding restriction endonuclease(s) specific for the site in the stem and the loop portion, or sequence of interest, is then relased as a linearized, single-stranded piece of DNA. This released (or cleaved) ss-DNA piece contains minimal, if any, sequence information either upstream 5' or downstream 3' from the previous double stranded stem portion which contains the restriction endonuclease cut site. In vivo tranfections using the DNA vector system described herein demonstrate the use of this system to produce ss-DNA in host cells.
Diagnostic aid for examination of pancreas function contains an acylated anilinobutyric acid of formula (I) (R1-R5=H, 1-4C alkyl, alkoxy or alkylthio, halo or CF3; R3 may also be OH or PhCH2O; Y=is not >6C alkyl or cycloalkyl or is not >16C opt. substd. aryl; Z=H or the equiv. of a salt-forming cation). (I) are already known from US 3780095 as choleretic agents and have now been shown to increase the exocrinal enzyme secretion of the gastrointestinal tract, esp. the secretion of digestive enzymes by the pancreas and stomach. The dose is much less than that required for a choleretic effect and (I) can be administered to humans or animals.
PURPOSE: To obtain a beauty lotion giving pearl-like luster having flowing pearl-like crystal, high safety and stability, and excellent appearance by including an alkyl glycoside, a higher alcohol and a surfactant. CONSTITUTION: This beauty lotion contains 0.0001-5% an alkyl glycoside as a 12-22C alkyl and a sugar selected from 5-6C monosaccharide, disaccharide, trisaccharide and an aminosaccharide (e.g. a mixture of 16C and 18C/grape sugar), 0.01-20% a higher alcohol (e.g. a mixture of 16C and 18C) and 0.01-10% a surfactant (e.g. polyoxyethylene polyoxypropylene cetyl ether) as active components. Furthermore, this beauty lotion is mixed with suitable amount of polyhydric alcohol, sugars, alcohol, drug, water, oil and fat, a water-soluble polymer, a coloring matter and an antioxidant. This beauty lotion has pearl-like luster without being affected by temperature variation, etc., stable for a long period of time, sustaining apparent advantage and keeps a high commercial value.
Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
Patients receive CBM588 PO BID, nivolumab IV over 30 minutes on day 1, and cabozantinib S-malate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients in the control group received 0.1% fluorometholone eye drops (0.1% fluorometholone + 0.05% tacrolimus eye drops for patients after corneal transplantation). The patients applied 0.1% fluorometholone eye drops 4 times daily for 10 weeks. Patients were instructed to continue with their usual ophthalmic medication regimens, such as topical antibacterial and antiviral drugs.
In a study of 10 patients with angiographically normal or minimally stenosed (less than 25% luminal diameter narrowing) coronary vessels, Dipyridamole Injection in a dose of 0.56 mg/kg infused over 4 minutes resulted in an average fivefold increase in coronary blood flow velocity compared to resting coronary flow velocity (range 3.8 to 7 times resting velocity). The mean time to peak flow velocity was 6.5 minutes from the start of the 4-minute infusion (range 2.5 to 8.7 minutes). Cardiovascular responses to the intravenous administration of Dipyridamole Injection when given to patients in the supine position include a mild but significant increase in heart rate of approximately 20% and mild but significant decreases in both systolic and diastolic blood pressure of approximately 2-8%, with vital signs returning to baseline values in approximately 30 minutes.

Mechanism of Action

Dipyridamole is a coronary vasodilator in man. The mechanism of vasodilation has not been fully elucidated, but may result from inhibition of uptake of adenosine, an important mediator of coronary vasodilation. The vasodilatory effects of dipyridamole are abolished by administration of the adenosine receptor antagonist theophylline.

How dipyridamole-induced vasodilation leads to abnormalities in thallium distribution and ventricular function is also uncertain but presumably represents a “steal” phenomenon in which relatively intact vessels dilate and sustain enhanced flow, leaving reduced pressure and flow across areas of hemodynamically important coronary vascular constriction.

Pharmacokinetics and Metabolism

Plasma dipyridamole concentrations decline in a triexponential fashion following intravenous infusion of dipyridamole, with half-lives averaging 3-12 minutes, 33-62 minutes and 11.6-15 hours. Two minutes following a 0.568 mg/kg dose of Dipyridamole Injection administered as a 4-minute infusion, the mean dipyridamole serum concentration is 4.6 ± 1.3 mcg/mL. The average plasma protein binding of dipyridamole is approximately 99%, primarily to α1-glycoprotein. Dipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile. The average total body clearance is 2.3-3.5 mL/min/kg, with an apparent volume of distribution at steady state of 1-2.5 L/kg and a central apparent volume of 3-5 liters.
This study takes place in two phases. Phase A consists of an open-label dose-escalation of L2-7001 through four dose levels. Ascending dose cohorts of five patients are studied. The safety and tolerability of L2-7001 is assessed in preparation for the second phase of the study and to estimate an MTD. Phase B involves randomization of 190 patients to (a) one of three dose levels of L2-7001 plus ART, (b) one of two dosing levels of Proleukin plus ART, or (c) ART alone. L2-7001 and Proleukin are given SC every 12 hours for the first 5 days of an 8-week cycle for three cycles. Serum IL-2 levels, soluble IL-2 receptor levels, and levels of pro-inflammatory cytokines are evaluated in 8 patients randomized to each treatment cohort of Phase B. All patients completing this phase of the protocol are eligible to be screened for enrollment in a maintenance use protocol which will allow for access to L2-7001.
Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.